16/05/2024  14:27:11 Var. +1.90 Volume Denaro14:27:12 Lettera14:28:55 Capitalizzazione di mercato Dividend Y. Rapporto P/E
90.15CHF +2.15% 3,662
Fatturato: 328,799.95
90.00Quantità in denaro: 20 90.25Quantità in lettera: 1 6.75 bill.CHF 0.89% 60.03

Descrizione business

Bachem is a listed technology-based company focused on peptide chemistry. The company provides a full range of services to the pharma and biotech industries. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients. A comprehensive catalog of biochemicals and exclusive custom syntheses for research labs complete the service portfolio. Headquartered in Switzerland with subsidiaries in Europe and the US, the group has a global reach with more experience and know-how than any other company in the industry. Towards its customers, Bachem shows total commitment to quality, innovation and partnership.
 

Consiglio di amministrazione & Consiglio di sorveglianza

CEO
Thomas Meier
Consiglio di amministrazione
Alain Schaffter, Dr. Anne-Kathrin Stoller, Dr. Günther Loidl, Torsten Wohr
Consiglio di sorveglianza
Dr. Kuno Sommer, Dr. Alex Fässler, Dr. h.c. Peter Grogg, Dr. Steffen Lang, Nicole Grogg Hötzer, Prof. Dr. Helma Wennemers
 

Dati aziendali

Name: Bachem Holding AG
Indirizzo: Hauptstraße 144,CH-4416 Bubendorf
Telefono: +41-58-595-2020
Fax: +41-58-595-2040
E-mail: sales.ch@bachem.com
Internet: www.bachem.com
Industria: Healthcare
Settore: Pharmaceutical Industry
Sub settore: Pharmaceuticals
Fine dell'anno finanziario: 31/12
Flottante libero: 38.00%
Data dell'IPO: 22/07/1998

Rapporti con gli investitori

Name: Daniel Grotzky
IR telefono: +41-58-595-2021
IR Fax: +41-58-595-2043
IR e-mail: ir@bachem.com

Company calendar

CW 30 | 25/07/2024 Interim Report 2nd Quarter/6 Months
CW 9 | 27/02/2025 Annual Report
 

Principali azionisti

a Ingro Finanz AG
 
52.10%
Altri
 
42.50%
Peter and Madeleine Grogg
 
5.40%